MTI-201 Phase I Clinical Trial
Modulation Therapeutics Inc. (MTI) is a clinical stage biotechnology company on a mission to improve outcomes for people with solid tumor cancers by commercializing the cancer defeating power of Targeted Alpha Therapy (TAT), novel Anti-Cancer Peptides, and Small Molecules. MTI has one cancer therapy in the clinic and two additional novel therapies expected in the clinic within months. MTI has received research funding support from the National Cancer Institute of the National Institutes of Health under several SBIR and STTR awards over the last 6 years, supplemented by grants and investments from several institutions, including the Melanoma Research Alliance and the Multiple Myeloma Research Foundation.
The lead therapy, MTI-201, a Targeting Alpha Radiotherapeutic for treating metastatic melanomas is on track to reach the market within 3 years with a companion diagnostic imaging agent. MTI-201 has received Orphan Drug and Fast Track status from the FDA.
MTI-301, a small molecular compound with multiple indications will enter the clinic this year followed by cyclic peptide MTI-101, also with multiple solid tumor cancer indications.
For our partners, exit within 3-5 years for the current pipeline of 4 novel first in class and best in class therapies targeting multiple diseases with severe unmet needs, is a realistic expectation.
MTI is a privately held Delaware corporation with primary operations based in Morgantown, West Virginia, USA.
The company is now raising Series "A" investment to advance this robust pipeline of cancer therapies through the initial clinical development milestones.
For Investment and Business Development inquiries:
Liberi Group (www.LiberiGroup.com)
Contact: Jan Roovers - Corporate Client Manager
For Company Inquiries:
Modulation Therapeutics, Inc. (MTI)
Contact: Tim Hazlehurst - COO